Positive Data on RECCE® 327 Against Neisseria gonorrhoeae in STD Animal Model

Highlights:

  • Statistically significant reduction of Neisseria gonorrhoeae bacteria in reproductive organs of female mice
  • RECCE® 327 outperformed market approved drug Meropenem in most instances

Sydney Australia, 4 May 2020: Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing a New Class of Broad-Spectrum Synthetic antibiotics, today announced positive efficacy showing significant antibacterial activity against Neisseria gonorrhoeae bacteria in mice treated with its lead compound RECCE® 327.

The study was conducted by an independent Contract Research Organisation to assess the dose-dependency of RECCE® 327 and in-vivo antibacterial activity against Neisseria gonorrhoeae (N. gonorrhoeae), a species of Gram-negative bacteria, and the second most common sexually transmitted infection (STI) globally.1 The recognised vaginal infection model met its primary endpoint of a reduction in bacterial load compared to vehicle infected control evaluated on the seventh day following dosing.

To read the full update click here.

About Recce Pharmaceuticals Ltd (ASX: RCE)

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad-spectrum activity designed to address the urgent global health problem of antibiotic-resistant superbugs.

Register Interest